Is SGMT or INBX more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -31.96% -30.57% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media prefer SGMT or INBX?

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 7 mentions for Inhibrx Biosciences and 4 mentions for Sagimet Biosciences. Inhibrx Biosciences' average media sentiment score of 1.23 beat Sagimet Biosciences' score of 0.97 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AKTS or SGMT more profitable?

Aktis Oncology's return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Sagimet Biosciences N/A -31.96% -30.57%

Does the media prefer AKTS or SGMT?

In the previous week, Aktis Oncology had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for Aktis Oncology and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat Aktis Oncology's score of 0.54 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SGMT or CGEM more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -31.96% -30.57% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media favor SGMT or CGEM?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat Cullinan Therapeutics' score of 0.80 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNKD or SGMT?

In the previous week, MannKind had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for MannKind and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat MannKind's score of 0.63 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NVAX or SGMT?

In the previous week, Novavax had 11 more articles in the media than Sagimet Biosciences. MarketBeat recorded 15 mentions for Novavax and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat Novavax's score of 0.19 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sagimet Biosciences (SGMT) Competitors

$10.31 +0.10 (+1.02%)

As of 03:34 PM Eastern

Compare

SGMT vs. INBX, AKTS, CGEM, MNKD, and NVAX

Should you buy Sagimet Biosciences stock or one of its competitors? Sagimet Biosciences's main competitors and comparable companies include Inhibrx Biosciences (INBX), Aktis Oncology (AKTS), Cullinan Therapeutics (CGEM), MannKind (MNKD), and Novavax (NVAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sagimet Biosciences compare to Inhibrx Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 7 mentions for Inhibrx Biosciences and 4 mentions for Sagimet Biosciences. Inhibrx Biosciences' average media sentiment score of 1.23 beat Sagimet Biosciences' score of 0.97 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sagimet Biosciences has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	319.35	-$51.04M	-$1.28	N/A
Inhibrx Biosciences	$1.30M	1,415.74	-$140.05M	-$8.88	N/A

Sagimet Biosciences presently has a consensus price target of $29.17, indicating a potential upside of 183.86%. Inhibrx Biosciences has a consensus price target of $197.50, indicating a potential upside of 57.96%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Sagimet Biosciences' return on equity of -31.96% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.51, meaning that its stock price is 251% more volatile than the broader market.

Summary

Sagimet Biosciences beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Aktis Oncology's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Sagimet Biosciences	N/A	-31.96%	-30.57%

Sagimet Biosciences has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	219.99	-$63.73M	-$0.82	N/A
Sagimet Biosciences	$2M	319.35	-$51.04M	-$1.28	N/A

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aktis Oncology had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for Aktis Oncology and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat Aktis Oncology's score of 0.54 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology presently has a consensus target price of $35.00, suggesting a potential upside of 31.56%. Sagimet Biosciences has a consensus target price of $29.17, suggesting a potential upside of 183.86%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Aktis Oncology beats Sagimet Biosciences on 8 of the 15 factors compared between the two stocks.

How does Sagimet Biosciences compare to Cullinan Therapeutics?

Sagimet Biosciences (NASDAQ:SGMT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sagimet Biosciences has higher revenue and earnings than Cullinan Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	319.35	-$51.04M	-$1.28	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Sagimet Biosciences has a beta of 3.37, indicating that its share price is 237% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Sagimet Biosciences' return on equity of -31.96% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Sagimet Biosciences currently has a consensus price target of $29.17, suggesting a potential upside of 183.86%. Cullinan Therapeutics has a consensus price target of $32.86, suggesting a potential upside of 43.86%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat Cullinan Therapeutics' score of 0.80 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sagimet Biosciences beats Cullinan Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Sagimet Biosciences compare to MannKind?

MannKind (NASDAQ:MNKD) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

In the previous week, MannKind had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for MannKind and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat MannKind's score of 0.63 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MannKind has higher revenue and earnings than Sagimet Biosciences. MannKind is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.84	$5.86M	-$0.13	N/A
Sagimet Biosciences	$2M	319.35	-$51.04M	-$1.28	N/A

MannKind presently has a consensus price target of $9.22, indicating a potential upside of 121.34%. Sagimet Biosciences has a consensus price target of $29.17, indicating a potential upside of 183.86%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Sagimet Biosciences has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Summary

Sagimet Biosciences beats MannKind on 8 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to Novavax?

Novavax (NASDAQ:NVAX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Novavax has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, indicating that its stock price is 237% more volatile than the broader market.

Novavax has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	3.76	$440.30M	-$1.52	N/A
Sagimet Biosciences	$2M	319.35	-$51.04M	-$1.28	N/A

53.0% of Novavax shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sagimet Biosciences has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Sagimet Biosciences	N/A	-31.96%	-30.57%

In the previous week, Novavax had 11 more articles in the media than Sagimet Biosciences. MarketBeat recorded 15 mentions for Novavax and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.97 beat Novavax's score of 0.19 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 48.38%. Sagimet Biosciences has a consensus price target of $29.17, indicating a potential upside of 183.86%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Sagimet Biosciences beats Novavax on 10 of the 16 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$638.07M	$4.04B	$7.32B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-8.02	11.72	271.20	24.17
Price / Sales	319.35	1,431.37	696.57	128.56
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	3.00	17.52	11.33	6.51
Net Income	-$51.04M	-$22.72M	$3.46B	$347.63M
7 Day Performance	-2.88%	4.50%	3.12%	1.53%
1 Month Performance	45.33%	11.99%	8.67%	5.17%
1 Year Performance	45.13%	60.24%	27.37%	17.69%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	3.2593 of 5 stars	$10.28 +0.6%	$29.17 +183.9%	+43.6%	$638.07M	$2M	N/A	8	Analyst Forecast
INBX Inhibrx Biosciences	2.6979 of 5 stars	$92.91 +1.0%	$150.00 +61.5%	+319.8%	$1.36B	N/A	N/A	166	News Coverage Positive News Analyst Forecast
AKTS Aktis Oncology	2.9316 of 5 stars	$24.69 -0.1%	$34.60 +40.2%	N/A	$1.32B	$10.06M	N/A	76	Gap Up
CGEM Cullinan Therapeutics	3.2034 of 5 stars	$20.42 -0.8%	$32.86 +60.9%	+166.4%	$1.31B	N/A	N/A	30	Analyst Upgrade
MNKD MannKind	2.9072 of 5 stars	$4.08 +4.5%	$9.22 +126.2%	-1.0%	$1.31B	$348.97M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. INBX, AKTS, CGEM, MNKD, and NVAX

How does Sagimet Biosciences compare to Inhibrx Biosciences?

Summary

How does Sagimet Biosciences compare to Aktis Oncology?

Summary

How does Sagimet Biosciences compare to Cullinan Therapeutics?

Summary

How does Sagimet Biosciences compare to MannKind?

Summary

How does Sagimet Biosciences compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. INBX, AKTS, CGEM, MNKD, and NVAX

How does Sagimet Biosciences compare to Inhibrx Biosciences?

Does the media prefer SGMT or INBX?

Do insiders and institutionals believe in SGMT or INBX?

Which has higher valuation & earnings, SGMT or INBX?

Do analysts recommend SGMT or INBX?

Is SGMT or INBX more profitable?

Which has more volatility and risk, SGMT or INBX?

Summary

How does Sagimet Biosciences compare to Aktis Oncology?

Is AKTS or SGMT more profitable?

Which has preferable valuation & earnings, AKTS or SGMT?

Do institutionals & insiders believe in AKTS or SGMT?

Does the media prefer AKTS or SGMT?

Do analysts rate AKTS or SGMT?

Summary

How does Sagimet Biosciences compare to Cullinan Therapeutics?

Do insiders and institutionals hold more shares of SGMT or CGEM?

Which has preferable valuation and earnings, SGMT or CGEM?

Which has more volatility & risk, SGMT or CGEM?

Is SGMT or CGEM more profitable?

Do analysts rate SGMT or CGEM?

Does the media favor SGMT or CGEM?

Summary

How does Sagimet Biosciences compare to MannKind?

Does the media favor MNKD or SGMT?

Which has more volatility & risk, MNKD or SGMT?

Do insiders and institutionals believe in MNKD or SGMT?

Which has stronger valuation and earnings, MNKD or SGMT?

Do analysts prefer MNKD or SGMT?

Is MNKD or SGMT more profitable?

Summary

How does Sagimet Biosciences compare to Novavax?

Which has more risk & volatility, NVAX or SGMT?

Which has higher earnings & valuation, NVAX or SGMT?

Do insiders and institutionals believe in NVAX or SGMT?

Is NVAX or SGMT more profitable?

Does the media favor NVAX or SGMT?

Do analysts recommend NVAX or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools